卵巢癌转移相关分子标记物及靶向性治疗药物的研究进展

Research Progress of Ovarian Cancer Metastasis Related Molecular Markers and Targeted Therapy

卵巢恶性肿瘤是女性生殖系统三大恶性肿瘤之一,其死亡率居妇科肿瘤的首位,已成为威胁女性健康的重要杀手。据美国国立癌症研究院调查显示,卵巢癌是与肿瘤相关的女性五大死因之一。上皮性卵巢癌占全部卵巢癌病例的近90%,且病情进展迅速,但由于缺乏早期临床表现和特异性症状,大多数患者就诊时已是晚期,手术治疗困难,预后较差。近年卵巢癌的发病率呈逐年上升趋势,易早期转移及浸润,是造成其死亡率高的原因。卵巢癌转移等恶性生物学行为已成为其研究热点。早期发现有效的卵巢癌转移相关分子标记物并对其进行靶向治疗是提高卵巢癌患者生存率的重要方法。除目前临床应用的糖类蛋白125(CA125)外,跨膜糖蛋白(CD44)、E-钙黏蛋白和E盒结合锌指蛋白1(ZEB1)等生物学分子有望成为诊断卵巢癌早期转移的分子标记物。

Ovarian malignant tumor is one of the three big malignant tumor in female reproductive system, the mortality rate is highest in gynecological tumors, which has become a serious threat to the female body health. According to the research of National Cancer Institute, ovarian cancer is one of the five female causes of death related to tumor. Epithelial ovarian cancer accounts for nearly 90% of all cases of ovarian cancer, and progress rapidly, but due to the lack of early clinical manifestations and specific symptoms, most are already late, when the patients see the doctors, surgery is difficult, and prognosis is poor. In recent years, there is an upward trend in the incidence of ovarian cancer, and it is easy to early metastasis and infiltration, which was the cause of the high mortality rate. Research on ovarian cancer metastasis of the malignant biological behavior has become a hot field.The early detection of effective ovarian cancer transfer related molecular markers and their targeted therapy is an important way to improve the survival rate of patients with ovarian cancer. In addition to the current clinical application of CA125,CD44,E-cadherin and ZEB1 is expected to become the molecular marker of early diagnosis of ovarian cancer metastasis.